Jessica Perl - 29 Apr 2026 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship: SVP, General Counsel, Corp Sec
Issuer ticker: EBS
Reported as of: 29 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 May 2026, 16:27:23 UTC
Prior SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Richard S. Lindahl, Attorney-in-fact

Key filing fact

Jessica Perl filed Form 4 for Emergent BioSolutions Inc. (EBS) on 01 May 2026.

Key facts

This page summarizes Jessica Perl's Form 4 filing for Emergent BioSolutions Inc. (EBS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 May 2026, 16:27.

Change

Previous filing in this sequence was filed on 05 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002043716 Primary reporting owner

Perl Jessica

Relationship: SVP, General Counsel, Corp Sec
Address: 300 PROFESSIONAL DRIVE, GAITHERSBURG
Signature: /s/ Richard S. Lindahl, Attorney-in-fact
Signature date: 01 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS transaction

Common Stock

Award

Transaction value
Shares: +104,282
Change %: +171%
Price: $0.000000^*
Shares after: 165,286
Date: 29 Apr 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

Footnote F2

Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.